Readystate Asset Management LP Acquires New Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Readystate Asset Management LP acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 179,518 shares of the biopharmaceutical company’s stock, valued at approximately $6,102,000.

A number of other large investors have also recently added to or reduced their stakes in CLDX. Novo Holdings A S acquired a new stake in Celldex Therapeutics in the 2nd quarter valued at about $31,458,000. Point72 Asset Management L.P. grew its stake in Celldex Therapeutics by 51.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after acquiring an additional 654,194 shares during the last quarter. Marshall Wace LLP lifted its holdings in Celldex Therapeutics by 53.3% in the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock valued at $50,995,000 after purchasing an additional 479,068 shares in the last quarter. Jennison Associates LLC lifted its holdings in Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after purchasing an additional 321,325 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its holdings in Celldex Therapeutics by 47.5% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 845,560 shares of the biopharmaceutical company’s stock valued at $31,294,000 after purchasing an additional 272,389 shares in the last quarter.

Insider Activity at Celldex Therapeutics

In other Celldex Therapeutics news, CEO Anthony S. Marucci purchased 11,500 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the acquisition, the chief executive officer now owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.80% of the stock is currently owned by insiders.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $26.58 on Thursday. Celldex Therapeutics, Inc. has a 1-year low of $22.93 and a 1-year high of $53.18. The firm’s 50-day simple moving average is $28.07 and its 200-day simple moving average is $34.16. The firm has a market cap of $1.76 billion, a P/E ratio of -10.34 and a beta of 1.57.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CLDX. The Goldman Sachs Group began coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 target price on the stock. Citigroup began coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 16th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $62.25.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.